Does Rallies show Form 4 insider transactions for RLAY?

Yes. Rallies tracks RLAY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RLAY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RLAY. It does not provide personalized investment advice.

RLAY (Relay Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Relay Therapeutics, Inc. Common Stock (RLAY) is a publicly traded Healthcare sector company. As of May 19, 2026, RLAY trades at $13.14 with a market cap of $2.34B and a P/E ratio of -7.54. RLAY moved +11.53% today. Year to date, RLAY is +47.92%; over the trailing twelve months it is +330.61%. Its 52-week range spans $1.78 to $17.32. Analyst consensus is strong buy with an average price target of $20.78. Rallies surfaces RLAY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RLAY stock inside the company?

Recent RLAY insider activity includes Catinazzo Thomas sold 17.72K, Catinazzo Thomas sold 972, Rahmer Peter sold 753, Bergstrom Donald A sold 1.49K, and Catinazzo Thomas sold 1.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RLAY Key Metrics

Key financial metrics for RLAY
Metric	Value
Price	$13.14
Market Cap	$2.34B
P/E Ratio	-7.54
EPS	$-1.56
Dividend Yield	0.00%
52-Week High	$17.32
52-Week Low	$1.78
Volume	9.32M
Avg Volume	0
Revenue (TTM)	$10.68M
Net Income	$-272.70M
Gross Margin	0.00%

Recent RLAY Insider Trades

Catinazzo Thomas sold 17.72K (~$227.84K) on May 14, 2026.
Catinazzo Thomas sold 972 (~$14.38K) on Apr 28, 2026.
Rahmer Peter sold 753 (~$11.14K) on Apr 28, 2026.
Bergstrom Donald A sold 1.49K (~$22.04K) on Apr 28, 2026.
Catinazzo Thomas sold 1.80K (~$27.00K) on Apr 9, 2026.

Latest RLAY News

Relay Therapeutics Shares Jump 15% after 60% Response Rate in Phase 2 Trial — May 19, 2026
Relay’s Zovegalisib Delivers 60% Volumetric Response, 89% Investigator-Reported Improvement — May 19, 2026
Relay Therapeutics Posts 44% ORR, Plans Phase 3 Triplet Trial in 2027 — Apr 27, 2026
Relay Therapeutics to Present Zovegalisib Data from 20 Vascular Anomaly Patients May 19-22 — Apr 2, 2026
Relay Therapeutics' Zovegalisib 400mg BID Fed Shows 11.1-Month PFS, Gains Breakthrough Status — Mar 16, 2026

RLAY Analyst Consensus

10 analysts cover RLAY: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.78.

Common questions about RLAY

Who is trading RLAY stock inside the company?: Recent RLAY insider activity includes Catinazzo Thomas sold 17.72K, Catinazzo Thomas sold 972, Rahmer Peter sold 753, Bergstrom Donald A sold 1.49K, and Catinazzo Thomas sold 1.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RLAY?: Yes. Rallies tracks RLAY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RLAY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RLAY. It does not provide personalized investment advice.